Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial.

"Here we show that T-DM1 actually increased overall survival for heavily pretreated patients with HER2-positive, metastatic breast cancer.

T-DM1, an experimental drug, showed promise in clinical trials against HER2-positive breast cancer. Patients who took the drug were free of disease longer than patients who utilized a standard ...

The drug, trastuzumab emtansine, commonly referred to as T-DM1, appears to be superior to the standard treatment for women with advanced HER2-positive breast cancer.

Commercially, T-DM1 should help protect Roche's breast cancer franchise, since Herceptin could be exposed to so-called "biosimilar" generic competition in Europe from around 2015.

But T-DM1 continued to be used as the standard second-line treatment without much evidence of its efficacy after the use of pertuzumab.

Trastuzumab emtansine (T–DM1) is a novel ADC that combines the humanized antibody trastuzumab and the potent antimicrotubule agent T-DM1 (derivative of maytansine) with use of a unique and highly ...

T-DM1, an drug antibody conjugate of trastuzumab and DM1, a cytotoxic agent, is active against metastatic HER2-positive breast cancer and in patients with residual disease after neoadjuvant HER2 ...

T-DM1 is an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1) and has demonstrated a benefit in patients with metastatic breast cancer that was previously treated with ...